Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | PANK3 | Q9H999 | 11/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4559943 | 0.87 | NPC1 (0.75) | NPC1RAB9APANK3MAPTSMN1; SMN2 | |
| SCHEMBL104337 | 0.87 | RAB9A (0.75) | NPC1RAB9APANK3MAPTSMN1; SMN2 | |
| SCHEMBL1575844 | 0.85 | NPC1 (0.56) | NPC1RAB9APANK3MAPTSMN1; SMN2 | |
| SCHEMBL6764523 | 0.84 | NPC1 (0.71) | NPC1RAB9APANK3MAPTSMN1; SMN2 | |
| SCHEMBL13234926 | 0.84 | LMNA (0.67) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL3568415 | 0.84 | KDM4E (0.67) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9465692 | 0.83 | NPC1 (0.65) | NPC1RAB9APANK3MAPTSMN1; SMN2 | |
| SCHEMBL14597010 | 0.83 | NPC1 (0.69) | NPC1RAB9APANK3MAPTSMN1; SMN2 | |
| SCHEMBL104586 | 0.83 | RAB9A (1.00) | NPC1RAB9APANK3MAPTSMN1; SMN2 | |
| SCHEMBL178415 | 0.82 | KDM4E (0.65) | NPC1RAB9APANK3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7816348-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| EP-1472225-B1 | 2-PIPERAZINE-PYRIDINES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2010-04-28 | — | — | EP | disclosed |
| US-20070219176-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | NPC1 1892/4885RAB9A 3030/4885PANK3 1942/4885 |
| US-20070219176-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | NPC1 1299/4885RAB9A 1527/4885PANK3 2418/4885 |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | NPC1 4547/4885RAB9A 1938/4885PANK3 795/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | NPC1 4566/4885RAB9A 2172/4885PANK3 784/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | NPC1 4566/4885RAB9A 2172/4885PANK3 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.